Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

BACKGROUND: In Italy HPV vaccination with the quadrivalent vaccine (Gardasil(®)) is offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine (Gardasil 9(®)) received the European market authorization in 2015 to protect, with only 2 doses, against around 90% of all HPV p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cost Eff Resour Alloc
Principais autores: Mennini, Francesco Saverio, Bonanni, Paolo, Bianic, Florence, de Waure, Chiara, Baio, Gianluca, Plazzotta, Giacomo, Uhart, Mathieu, Rinaldi, Alessandro, Largeron, Nathalie
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5504713/
https://ncbi.nlm.nih.gov/pubmed/28701899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-017-0073-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados